Concurrent Therapy of Chronic Lymphocytic Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Utilizing CD19-targeted CAR T-cells

Overview

Journal Leuk Lymphoma

Specialties Hematology
Oncology

Date 2017 Oct 19

PMID 29043880

Citations 2

Authors

Mark B Geyer

Shwetha H Manjunath

Andrew G Evans

Jae H Park

Marco L Davila

Corey S Cutler

Xiuyan Wang

Yongzeng Wang

Brigitte Senechal

Isabelle Riviere

Michel Sadelain

Jane L Liesveld

Renier J Brentjens

Affiliations

Soon will be listed here.

Citing Articles

Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.

Zeng Q, Xiang B, Liu Z Cancer Med. 2021; 10(24):8741-8753.

PMID: 34761879 PMC: 8683551. DOI: 10.1002/cam4.4413.

Depletion of high-content CD14 cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.

Wang X, Borquez-Ojeda O, Stefanski J, Du F, Qu J, Chaudhari J Mol Ther Methods Clin Dev. 2021; 22:377-387.

PMID: 34514029 PMC: 8411225. DOI: 10.1016/j.omtm.2021.06.014.

References

Fraietta J, Beckwith K, Patel P, Ruella M, Zheng Z, Barrett D . Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016; 127(9):1117-27. PMC: 4778162. DOI: 10.1182/blood-2015-11-679134. View

Pegram H, Lee J, Hayman E, Imperato G, Tedder T, Sadelain M . Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012; 119(18):4133-41. PMC: 3359735. DOI: 10.1182/blood-2011-12-400044. View

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C . Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009; 32(2):169-80. PMC: 2683970. DOI: 10.1097/CJI.0b013e318194a6e8. View

Wetzler M, Sanford B, Kurtzberg J, Deoliveira D, Frankel S, Powell B . Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007; 109(10):4164-7. PMC: 1885493. DOI: 10.1182/blood-2006-09-045351. View

Ramsay A, Clear A, Fatah R, Gribben J . Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012; 120(7):1412-21. PMC: 3423779. DOI: 10.1182/blood-2012-02-411678. View

Chakhachiro Z, Yin C, Abruzzo L, Aladily T, Barron L, Banks H . B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia: A Report of Four Cases. Am J Clin Pathol. 2015; 144(2):333-40. DOI: 10.1309/AJCPXE5VMONMVLZ0. View

Turtle C, Hay K, Hanafi L, Li D, Cherian S, Chen X . Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol. 2017; 35(26):3010-3020. PMC: 5590803. DOI: 10.1200/JCO.2017.72.8519. View

McClanahan F, Hanna B, Miller S, Clear A, Lichter P, Gribben J . PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood. 2015; 126(2):203-11. PMC: 4497961. DOI: 10.1182/blood-2015-01-622936. View

10.

Riches J, Davies J, McClanahan F, Fatah R, Iqbal S, Agrawal S . T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2012; 121(9):1612-21. PMC: 3587324. DOI: 10.1182/blood-2012-09-457531. View

11.

Mohamed A, Compean R, Dan M, Smith M, Al-Katib A . Clonal evolution of chronic lymphocytic leukemia to acute lymphoblastic leukemia. Cancer Genet Cytogenet. 1996; 86(2):143-6. DOI: 10.1016/0165-4608(95)00202-2. View

12.

Turtle C, Hanafi L, Berger C, Gooley T, Cherian S, Hudecek M . CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016; 126(6):2123-38. PMC: 4887159. DOI: 10.1172/JCI85309. View

13.

Pistoia V, Roncella S, Di Celle P, Sessarego M, Cutrona G, Cerruti G . Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors. Blood. 1991; 78(3):797-804. View

14.

Zhao Z, Condomines M, van der Stegen S, Perna F, Kloss C, Gunset G . Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell. 2015; 28(4):415-428. PMC: 5003056. DOI: 10.1016/j.ccell.2015.09.004. View

15.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

16.

Porter D, Hwang W, Frey N, Lacey S, Shaw P, Loren A . Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015; 7(303):303ra139. PMC: 5909068. DOI: 10.1126/scitranslmed.aac5415. View